Paladin Labs Price Target Raised to $50.00 at Paradigm Capital (PLB)

Paladin Labs (TSE: PLB) had its price target boosted by Paradigm Capital from $46.00 to $50.00 in a research report released on Tuesday morning. Paradigm Capital currently has a hold rating on the stock.

Shares of Paladin Labs opened at 47.45 on Tuesday. Paladin Labs has a one year low of $36.76 and a one year high of $51.89. The stock’s 50-day moving average is currently $45.33. The company has a market cap of $968.1 million and a P/E ratio of 15.65.

Other equities research analysts have also recently issued reports about the stock. Analysts at National Bank of Greece raised their price target on shares of Paladin Labs from $51.00 to $57.00 in a research note to investors on Friday, March 1st. They now have an outperform rating on the stock. Separately, analysts at Canaccord Genuity initiated coverage on shares of Paladin Labs in a research note to investors on Thursday, January 17th. They set a buy rating and a $56.00 price target on the stock. Finally, analysts at GMP Securities initiated coverage on shares of Paladin Labs in a research note to investors on Tuesday, January 15th. They set a buy rating on the stock.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Leave a Reply

Recent Stories

Liver Disease Risk Might be Lowered by Drinking Coffee
Liver Disease Risk Might be Lowered by Drinking Coffee
Construction Workers in Dubai Strike for Better Pay and Overtime
Construction Workers in Dubai Strike for Better Pay and Overtime
Bashar al-Assad says no to Stepping Down as Syria President
Bashar al-Assad says no to Stepping Down as Syria President
CDC: Mental Disorders affect close to 1 out of 5 Children
CDC: Mental Disorders affect close to 1 out of 5 Children
Airplanes and Airlines to be filled to Capacity this Summer
Airplanes and Airlines to be filled to Capacity this Summer
Erectile Dysfunction Tied to Pain Killer Medication
Erectile Dysfunction Tied to Pain Killer Medication
© 2010-2013 The Utah People's Post, Inc. · RSS. · Subscribe Subscribe